The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
When can active surveillance be less active? Prediction of long-term nonreclassification for men with low-risk prostate cancer.
 
Matthew R. Cooperberg
Honoraria - Takeda
Consulting or Advisory Role - Astellas Pharma; Bayer; Dendreon; Janssen; MDxHealth; Myriad Pharmaceuticals
Research Funding - GenomeDx (Inst); Genomic Health (Inst); Myriad Pharmaceuticals (Inst)
 
Anna V Faino
No Relationships to Disclose
 
Lisa F Newcomb
No Relationships to Disclose
 
Peter Carroll
No Relationships to Disclose
 
James T Kearns
No Relationships to Disclose
 
James D. Brooks
No Relationships to Disclose
 
Michael Fabrizio
No Relationships to Disclose
 
Martin Gleave
Stock and Other Ownership Interests - OncoGenex
Honoraria - Abbvie; Astellas Pharma; Bayer; Janssen; Oncogenex; Sanofi
Consulting or Advisory Role - Abbvie; Astellas Pharma; Bayer; Janssen; Oncogenex; Sanofi
Research Funding - Astellas Pharma; Bayer; Janssen
Patents, Royalties, Other Intellectual Property - OncoGenex - OGX-011, OGX-427
 
Todd Matthew Morgan
Consulting or Advisory Role - MDxHealth; Myriad Genetics
Research Funding - GenomeDx (Inst); MDxHealth (Inst); Myriad Genetics (Inst)
 
Atreya Dash
No Relationships to Disclose
 
Peter Nelson
Consulting or Advisory Role - Astellas Pharma; Janssen Oncology; Roche/Genentech
 
Ian Murchie Thompson
Consulting or Advisory Role - Magforce; Profound Medical
Patents, Royalties, Other Intellectual Property - I have several patents with colleagues involving novel biomarkers for cancer and two devices for sexual dysfunction and urinary incontinence. No revenues at this time and our University IP office is working with industry to determine if these can be comme
 
Andrew Wagner
No Relationships to Disclose
 
Daniel W. Lin
Consulting or Advisory Role - Astellas Pharma
Research Funding - GenomeDx (Inst); Genomic Health (Inst); MDxHealth (Inst)
 
Yingye Zheng
No Relationships to Disclose